imatinib mesylate has been researched along with Angor Pectoris in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abruzzese, E; Annunziata, M; Baratè, C; Binotto, G; Bonifacio, M; Breccia, M; Caocci, G; Cattaneo, D; De Gregorio, F; Elena, C; Foà, R; Fozza, C; Galimberti, S; Iurlo, A; La Nasa, G; Luciano, L; Martino, B; Molica, M; Mulas, O; Orlandi, EM; Russo Rossi, A; Sgherza, N; Trawinska, MM | 1 |
| Dirschinger, J; Goos, C; Hausleiter, J; Heemann, U; Kastrati, A; Mehilli, J; Pache, J; Pogatsa-Murray, G; Schömig, A; Schühlen, H; Zohlnhöfer, D | 1 |
1 trial(s) available for imatinib mesylate and Angor Pectoris
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Benzamides; Coronary Angiography; Coronary Disease; Coronary Restenosis; Creatinine; Double-Blind Method; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Secondary Prevention; Stents | 2005 |
1 other study(ies) available for imatinib mesylate and Angor Pectoris
| Article | Year |
|---|---|
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aniline Compounds; Antineoplastic Agents; Brain Ischemia; Dasatinib; Disease Susceptibility; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myocardial Infarction; Nitriles; Peripheral Vascular Diseases; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Retrospective Studies | 2019 |